Clene, Inc. (CLNN)
4.08
+0.06
(+1.49%)
USD |
NASDAQ |
Oct 02, 16:00
4.04
-0.04
(-0.98%)
After-Hours: 20:00
Clene Net Income (Quarterly) : -13.42M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -13.42M |
| March 31, 2026 | -8.091M |
| December 31, 2025 | -9.226M |
| September 30, 2025 | -8.777M |
| June 30, 2025 | -7.419M |
| March 31, 2025 | -0.751M |
| December 31, 2024 | -13.55M |
| September 30, 2024 | -7.986M |
| June 30, 2024 | -6.785M |
| March 31, 2024 | -11.08M |
| December 31, 2023 | -10.17M |
| September 30, 2023 | -2.418M |
| June 30, 2023 | -25.14M |
| March 31, 2023 | -11.77M |
| December 31, 2022 | -1.054M |
| September 30, 2022 | -10.98M |
| June 30, 2022 | -4.534M |
| Date | Value |
|---|---|
| March 31, 2022 | -13.35M |
| December 31, 2021 | 4.423M |
| September 30, 2021 | 28.94M |
| June 30, 2021 | -3.351M |
| March 31, 2021 | -39.76M |
| December 31, 2020 | 0.778M |
| September 30, 2020 | -10.30M |
| June 30, 2020 | -5.819M |
| March 31, 2020 | -3.941M |
| December 31, 2019 | -0.192M |
| September 30, 2019 | -0.1097M |
| June 30, 2019 | -0.0595M |
| March 31, 2019 | -0.0926M |
| December 31, 2018 | -0.1509M |
| September 30, 2018 | -0.0726M |
| June 30, 2018 | -0.0156M |
| March 31, 2018 | -0.0382M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0858M |
| Brainstorm Cell Therapeutics, Inc. | -3.855M |
| Summit Therapeutics, Inc. | -215.70M |
| Kezar Life Sciences, Inc. | -5.756M |
| Protara Therapeutics, Inc. | -21.67M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.09M |
| Total Expenses (Quarterly) | 13.51M |
| EPS Diluted (Quarterly) | -1.084 |
| Enterprise Value | 64.81M |
| Gross Profit Margin (Quarterly) | -332.2% |
| Profit Margin (Quarterly) | -14.92K% |
| Earnings Yield | -86.09% |
| Normalized Earnings Yield | -62.12 |